AR
DNLI icon

Advisory Research’s Denali Therapeutics DNLI Stock Holding History

Advisory Research’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-27,185
Closed -$974K – 319
2020
Q3 		$974K Sell
27,185
-9,951
-27% -$300K 0.09% 179
2020
Q2 		$898K Buy
37,136
+13,360
+56% +$314K 0.08% 182
2020
Q1 		$416K Buy
+23,776
New +$496K 0.03% 212

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Advisory Research's DNLI Position: Q4 2020 in Review

Advisory Research sold out of Denali Therapeutics (DNLI) in Q4 2020, closing a stake of 27,185 shares — an estimated $974K sold.

Advisory Research first reported a position in DNLI in Q1 2020 and held it in 3 quarters. The position peaked at $974K in Q3 2020. 205 funds tracked by Wall St. Rank hold DNLI as of Q4 2020.

  • Advisory Research reported no remaining Denali Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Advisory Research sold 27,185 Denali Therapeutics shares in Q4 2020, an estimated $974K.
  • Advisory Research first reported a position in Denali Therapeutics in Q1 2020 and held it in 3 quarters.
  • Advisory Research's Denali Therapeutics position peaked at $974K in Q3 2020.
  • 205 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2020.

Based on Advisory Research's 13F filing for Q4 2020, filed 12 Feb 2021.